E-EDV-D682

E-EDV-D682 is an investigational cancer therapy developed by EnGeneIC Cancer Therapeutics that utilizes the EnGeneIC Delivery Vehicle (EDV) platform. The platform consists of bacterially-derived, non-living nanocells (minicells) that are targeted to tumor cells via a bispecific antibody. In this specific formulation, the nanocells are targeted to the Epidermal Growth Factor Receptor (EGFR) and packaged with PNU-159682, a super-cytotoxic secondary metabolite of nemorubicin. PNU-159682 is significantly more potent than traditional anthracyclines like doxorubicin. The EDV system is designed to deliver these highly toxic payloads directly into the intracellular compartment of cancer cells, thereby bypassing multidrug resistance (MDR) mechanisms and reducing systemic side effects. The therapy has been evaluated in clinical trials for advanced pancreatic ductal adenocarcinoma (PDAC) and other EGFR-expressing solid tumors, often in combination with immune-adjuvants like alpha-galactosylceramide (E-EDV-D682/GC).

Other names

EDV nanocells with PNU-159682PNU-159682-loaded EDVPNU159682-loaded EDVPNU 159682-loaded EDVEGFR-targeted EDV nanocells packaged with PNU-159682EnGeneIC Dream Vectors